Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device

News You Need to Know Today
Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device
Monday, June 15, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Abbott recalls heart device monitoring system due to malfunction risk

The new recall impacts thousands of portable systems. A software update is now available that should resolve any issues. 

READ MORE >
Recall | Product recall
Share on Twitter Share on Facebook Share on Linkedin

Abbott recalls heart device monitoring system due to malfunction risk

Share on Twitter Share on Facebook Share on Linkedin
Recall | Product recall
The new recall impacts thousands of portable systems. A software update is now available that should resolve any issues. 
READ MORE >

Redo TAVR with balloon-expandable valves linked to positive outcomes, key improvements

Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific. 

READ MORE >
Sapien 3 Ultra Resilia TAVR valves
Share on Twitter Share on Facebook Share on Linkedin

Redo TAVR with balloon-expandable valves linked to positive outcomes, key improvements

Share on Twitter Share on Facebook Share on Linkedin
Sapien 3 Ultra Resilia TAVR valves
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific. 
READ MORE >

FDA clears new computer-assisted device for removing clots in stroke patients

The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.

READ MORE >
California-based Penumbra has received U.S. Food and Drug Administration (FDA) clearance Thunderbolt, a new computer-assisted vacuum thrombectomy (CAVT) device designed to treat acute ischemic stroke.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears new computer-assisted device for removing clots in stroke patients

Share on Twitter Share on Facebook Share on Linkedin
California-based Penumbra has received U.S. Food and Drug Administration (FDA) clearance Thunderbolt, a new computer-assisted vacuum thrombectomy (CAVT) device designed to treat acute ischemic stroke.
The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
READ MORE >

Featured Articles

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital

A failed TAVR procedure has left one family unsure about where things went wrong. 

READ MORE >
Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.
Share on Twitter Share on Facebook Share on Linkedin

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital

Share on Twitter Share on Facebook Share on Linkedin
Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.
A failed TAVR procedure has left one family unsure about where things went wrong. 
READ MORE >

Subtle heart changes linked to heightened risk of cancer

MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer. 

READ MORE >
heart data research doctor cardiologist AI
Share on Twitter Share on Facebook Share on Linkedin

Subtle heart changes linked to heightened risk of cancer

Share on Twitter Share on Facebook Share on Linkedin
heart data research doctor cardiologist AI
MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer. 
READ MORE >

Death after TAVR: New data support use of better patient assessments

A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients? 

READ MORE >
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
Share on Twitter Share on Facebook Share on Linkedin

Death after TAVR: New data support use of better patient assessments

Share on Twitter Share on Facebook Share on Linkedin
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients? 
READ MORE >

In Case You Missed It

FDA approves first-in-class hypertension drug from AstraZeneca

Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.

READ MORE >
How aldosterone works to treat hypertension.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves first-in-class hypertension drug from AstraZeneca

Share on Twitter Share on Facebook Share on Linkedin
How aldosterone works to treat hypertension.
Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.
READ MORE >

Cardiologists scramble to prepare for mandatory heart failure payment model

Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 

READ MORE >
Samuel Jones, MD, MPH, director of inpatient electrophysiology at the Memorial Hospital, Chattanooga Heart Institute, discusses concerns over new heart failure Medicare Ambulatory Specialty Model payment model that starts on Jan. 1, 2027.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists scramble to prepare for mandatory heart failure payment model

Share on Twitter Share on Facebook Share on Linkedin
Samuel Jones, MD, MPH, director of inpatient electrophysiology at the Memorial Hospital, Chattanooga Heart Institute, discusses concerns over new heart failure Medicare Ambulatory Specialty Model payment model that starts on Jan. 1, 2027.
Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 
READ MORE >

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business

Boston Scientific has invested heavily in Georgia-based MiRus, a rising name in the competitive TAVR landscape.

READ MORE >
money business cash flow dollar. Kingsway Financial Services, a Chicago-based holding company with subsidiaries in several industries, has acquired New Jersey-based Digital Diagnostics Imaging (DDI) for $11 million. The transaction was funded with $5.4 million in cash and $5.6 million in debt financing.
Share on Twitter Share on Facebook Share on Linkedin

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business

Share on Twitter Share on Facebook Share on Linkedin
money business cash flow dollar. Kingsway Financial Services, a Chicago-based holding company with subsidiaries in several industries, has acquired New Jersey-based Digital Diagnostics Imaging (DDI) for $11 million. The transaction was funded with $5.4 million in cash and $5.6 million in debt financing.
Boston Scientific has invested heavily in Georgia-based MiRus, a rising name in the competitive TAVR landscape.
READ MORE >

In Other News

Nvidia partners with clinical note-taking company to improve suite of AI models

The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.

READ MORE >
Nvidia
Share on Twitter Share on Facebook Share on Linkedin

Nvidia partners with clinical note-taking company to improve suite of AI models

Share on Twitter Share on Facebook Share on Linkedin
Nvidia
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
READ MORE >

Humana exits $900M position in end-of-life provider Gentiva

The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.

READ MORE >
Humana
Share on Twitter Share on Facebook Share on Linkedin

Humana exits $900M position in end-of-life provider Gentiva

Share on Twitter Share on Facebook Share on Linkedin
Humana
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup